In mouse models of NPM1-mutated/FLT3-ITD AML, venetoclax plus menin inhibitor was superior to the menin inhibitor alone, in eliminating leukemic cells (including leukemia stem/progenitor cells), decreasing Bcl-2 and Bcl-xL levels [83], and significantly prolonging mice OS [83]. The gene discussed is BCL2; the disease is leukemia.